Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOLGA perioperative durvalumab, tremelimumab, and enfortumab vedotin in cisplatin-ineligible or cisplatin-refusing muscle-invasive bladder cancer
NL-OMON54296Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab, tremelimumab and enfortumab vedotin in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma (TCC) (4 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability, Pathologic complete response rate and 1 more. Started May 2022; status: recruiting.
02
Drugs
durvalumabtremelimumabenfortumab vedotin
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON54296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54296.